Vor Biopharma
50 hedge funds and large institutions have $67.6M invested in Vor Biopharma in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 16 closing their positions.
500% more call options, than puts
Call options by funds: $78K | Put options by funds: $13K
102% more capital invested
Capital invested by funds: $33.5M → $67.6M (+$34.2M)
0.94% more ownership
Funds ownership: 3.5% → 4.44% (+0.94%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 54 → 50 (-4)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$528K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$165K |
| 4 |
Morgan Stanley
New York
|
+$112K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$95.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.73M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$540K |
| 3 |
Renaissance Technologies
New York
|
-$188K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$160K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$65.8K |
VOR Hedge Fund Activity: Q4 2024 in Review
50 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2024, worth a combined $67.6M — up 102% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VOR and 12 opened new positions — a net loss of 4 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was RA Capital Management, adding an estimated $14M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $1.73M sold.
- 50 institutional investors held Vor Biopharma (VOR) as of Q4 2024, down from 54 in Q3 2024.
- Funds reported $67.6M of Vor Biopharma stock for Q4 2024, up 102% quarter-over-quarter.
- 12 funds opened new Vor Biopharma positions in Q4 2024 and 16 closed out, a net change of -4 holders.
- The largest Vor Biopharma buyer in Q4 2024 was RA Capital Management, an estimated $14M added.
- The largest Vor Biopharma seller in Q4 2024 was Hudson Bay Capital Management, an estimated $1.73M sold.
Based on aggregated 13F filings for Q4 2024.